EA200200808A1 - Модифицированные цитокины, предназначенные для применения в терапии рака - Google Patents

Модифицированные цитокины, предназначенные для применения в терапии рака

Info

Publication number
EA200200808A1
EA200200808A1 EA200200808A EA200200808A EA200200808A1 EA 200200808 A1 EA200200808 A1 EA 200200808A1 EA 200200808 A EA200200808 A EA 200200808A EA 200200808 A EA200200808 A EA 200200808A EA 200200808 A1 EA200200808 A1 EA 200200808A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
modified cytokines
intended
cytokines intended
modified
Prior art date
Application number
EA200200808A
Other languages
English (en)
Other versions
EA007838B1 (ru
Inventor
Анджело Корти
Original Assignee
Фондазионе Чентро Сан Раффаэле Дель Монте Табор
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фондазионе Чентро Сан Раффаэле Дель Монте Табор filed Critical Фондазионе Чентро Сан Раффаэле Дель Монте Табор
Publication of EA200200808A1 publication Critical patent/EA200200808A1/ru
Publication of EA007838B1 publication Critical patent/EA007838B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
    • C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)

Abstract

В заявке описаны производные цитокинов, которые обладают способностью возвращать в исходное состояние сосуды опухоли и антигенпрезентирующие клетки, и их применение в качестве противораковых агентов.Отчет о международном поиске был опубликован 2002.01.31.
EA200200808A 2000-02-15 2001-02-13 Конъюгированные цитокины, используемые для терапии опухолей EA007838B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI000249A IT1317835B1 (it) 2000-02-15 2000-02-15 Citochine modificate per uso nella terapia del cancro.
PCT/EP2001/001543 WO2001061017A2 (en) 2000-02-15 2001-02-13 Modified cytokines for use in cancer therapy

Publications (2)

Publication Number Publication Date
EA200200808A1 true EA200200808A1 (ru) 2003-02-27
EA007838B1 EA007838B1 (ru) 2007-02-27

Family

ID=11444017

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200808A EA007838B1 (ru) 2000-02-15 2001-02-13 Конъюгированные цитокины, используемые для терапии опухолей

Country Status (29)

Country Link
US (4) US7150869B2 (ru)
EP (2) EP2080804A1 (ru)
JP (1) JP4836384B2 (ru)
KR (1) KR100888761B1 (ru)
CN (2) CN1446261B (ru)
AT (1) ATE424461T1 (ru)
AU (1) AU784173C (ru)
BG (1) BG65931B1 (ru)
BR (1) BR0108391A (ru)
CA (1) CA2399986C (ru)
CY (1) CY1109034T1 (ru)
CZ (1) CZ299486B6 (ru)
DE (1) DE60137835D1 (ru)
DK (1) DK1255845T3 (ru)
EA (1) EA007838B1 (ru)
ES (1) ES2322234T3 (ru)
HK (1) HK1048649B (ru)
HU (1) HU227894B1 (ru)
IL (2) IL150984A0 (ru)
IT (1) IT1317835B1 (ru)
MX (1) MXPA02007899A (ru)
NO (1) NO330913B1 (ru)
PL (1) PL207263B1 (ru)
PT (1) PT1255845E (ru)
SI (1) SI1255845T1 (ru)
SK (1) SK287550B6 (ru)
UA (1) UA85365C2 (ru)
WO (1) WO2001061017A2 (ru)
ZA (1) ZA200206450B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7309694B2 (en) 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7109303B2 (en) 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
AU2006200762B2 (en) * 2000-02-24 2008-08-21 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
DE60121733T2 (de) 2000-02-24 2007-08-09 Philogen S.P.A. Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen
ATE373503T1 (de) 2002-02-06 2007-10-15 Ares Trading Sa Tumornekrosefaktor in kombination mit interferon in demyelinierungskrankheiten
EP1346729A1 (en) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Targeting of myocardial angiogenesis through CD13/APN
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
CA2521109A1 (en) * 2003-03-31 2004-10-28 Greenville Hospital System Anti-tumor vasculature effects of human serum albumin derivatives
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
EP2364995A1 (en) 2004-12-23 2011-09-14 Molmed SpA Conjugation product
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
AU2009248105B2 (en) * 2008-05-13 2013-10-31 Molmed S.P.A. Conjugates for the treatment of mesothelioma
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
EP3882257A1 (en) 2020-03-20 2021-09-22 Ospedale San Raffaele S.r.l. Ngr conjugates and uses thereof
WO2023170209A1 (en) 2022-03-09 2023-09-14 Ospedale San Raffaele Srl Fusion proteins and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5811512A (en) 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
EP0733066B1 (en) 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting methods and compounds
US5888814A (en) 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5891418A (en) 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
DE69734887T2 (de) * 1996-09-10 2006-08-24 The Burnham Institute, La Jolla Tumor findende moleküle, davon abstammende konjugate und verfahren zu deren verwendung
US6576239B1 (en) * 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6759509B1 (en) * 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
WO1999013329A1 (en) * 1997-09-10 1999-03-18 The Burnham Institute Methods of identifying molecules that home to angiogenic vasculature in tumors
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.

Also Published As

Publication number Publication date
SK287550B6 (sk) 2011-01-04
US20030157055A1 (en) 2003-08-21
ZA200206450B (en) 2003-04-24
ITMI20000249A1 (it) 2001-08-15
CN1446261A (zh) 2003-10-01
US7476721B2 (en) 2009-01-13
NO330913B1 (no) 2011-08-15
CN1446261B (zh) 2010-05-05
WO2001061017A2 (en) 2001-08-23
ES2322234T3 (es) 2009-06-18
HK1048649B (zh) 2009-08-14
SI1255845T1 (sl) 2009-08-31
HUP0300005A3 (en) 2005-09-28
CN1853730B (zh) 2013-07-24
AU4413501A (en) 2001-08-27
CZ20023093A3 (cs) 2003-02-12
NO20023833L (no) 2002-10-15
ITMI20000249A0 (it) 2000-02-15
PL362670A1 (en) 2004-11-02
US20100196458A1 (en) 2010-08-05
SK11512002A3 (sk) 2003-02-04
EP1255845B1 (en) 2009-03-04
HK1048649A1 (en) 2003-04-11
PL207263B1 (pl) 2010-11-30
US20050265965A1 (en) 2005-12-01
AU784173B2 (en) 2006-02-16
WO2001061017A3 (en) 2002-01-31
MXPA02007899A (es) 2004-09-10
US7150869B2 (en) 2006-12-19
CY1109034T1 (el) 2014-07-02
CZ299486B6 (cs) 2008-08-13
EP1255845A2 (en) 2002-11-13
US20070041939A1 (en) 2007-02-22
CA2399986C (en) 2012-10-02
NO20023833D0 (no) 2002-08-13
DE60137835D1 (de) 2009-04-16
US7622556B2 (en) 2009-11-24
BG65931B1 (bg) 2010-05-31
CN1853730A (zh) 2006-11-01
BG106999A (bg) 2003-04-30
HU227894B1 (en) 2012-05-29
KR100888761B1 (ko) 2009-03-17
UA85365C2 (ru) 2009-01-26
EA007838B1 (ru) 2007-02-27
IT1317835B1 (it) 2003-07-15
ATE424461T1 (de) 2009-03-15
AU784173C (en) 2006-09-07
BR0108391A (pt) 2003-03-11
KR20020089348A (ko) 2002-11-29
CA2399986A1 (en) 2001-08-23
HUP0300005A2 (hu) 2003-04-28
JP2004520801A (ja) 2004-07-15
EP2080804A1 (en) 2009-07-22
DK1255845T3 (da) 2009-06-22
IL150984A0 (en) 2003-02-12
JP4836384B2 (ja) 2011-12-14
IL150984A (en) 2011-04-28
PT1255845E (pt) 2009-04-09

Similar Documents

Publication Publication Date Title
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
BR0114829A (pt) Novos compostos
EA200100369A1 (ru) Химиотерапия рака с помощью ацетилдиналина в комбинации с гемцитабином, кэйпцитабином или цис-платиной
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
BR0114814A (pt) Composições compreendendo composto de modafinila e seu uso
DE60008400D1 (de) Triazolopyrimidinderivate
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
MX9201763A (es) Derivados de pirimidina para aumentar la actividad antitumores.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
DE60134740D1 (de) Zusammensetzung zur potenzierung von krebs-chemotherapeutika
NO306292B1 (no) Triaryletylenderivater for anvendelse innen terapi
MD2228G2 (ru) Использование изотиоуроновых производных в лечении и профилактике атонии кишечника
MD2053C2 (ru) Лекарственное средство с интерферониндуцирующим действием
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması
BR0207681A (pt) Combinações sinérgicas de ligantes do receptor retinóide e agentes citotóxicos selecionados para tratamento do câncer
CA105166S (en) Combination stool and table base component
NO996023D0 (no) Bordkort med skjult oppdragbar bakside, skjult under kulen øverst på kortet

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU